Monthly
US$200
Billed every month
Sign in to subscribeAs of 13 November 2026, for Mometasone Furoate Cream, 16 applications are listed as under review at China's CDE; 5 companies have filed new generic applications in 2026; the chemical-drug catalogue lists 0 holders.
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 3 applicationsNo longer listed under review: 2 applications
Current coverage may be incomplete
The brand names come from the US FDA Orange Book and describe US listing records for this active ingredient. They do not indicate that products under these brand names are approved or sold in China, or that Chinese applicants are affiliated with US holders.
Orange Book source export date: 2026/11/06. Version: 2026-11-06.
Showing 5 of 6 distinct brand names.
A brand with different source forms or statuses can appear on multiple rows and in both groups. Distinct brand names are counted once globally, with a limit of five.
Verified official English dosage form: Cream. Listings are grouped by the source dosage form and route; records without a clear correspondence are listed in the other group. Grouping does not establish product equivalence.
No listings in this group among the displayed brand names.
| Brand name | Applicant (source text) | Application number | Dosage form (source text) | Route (source text) | Marketing status (source text) | Approval date |
|---|---|---|---|---|---|---|
| ASMANEX TWISTHALER | ORGANON LLC | NDA 021067 · Product no. 001 | POWDER | INHALATION | HUMAN PRESCRIPTION DRUG | 2005/03/30 |
| ASMANEX TWISTHALER | ORGANON LLC | NDA 021067 · Product no. 002 | POWDER | INHALATION | HUMAN PRESCRIPTION DRUG | 2008/02/01 |
| ASMANEX HFA | ORGANON LLC | NDA 205641 · Product no. 001, 002 | AEROSOL, METERED | INHALATION | HUMAN PRESCRIPTION DRUG | 2014/04/25 |
| SINUVA | INTERSECT ENT INC | NDA 209310 · Product no. 001 | IMPLANT | IMPLANTATION | HUMAN PRESCRIPTION DRUG | 2017/12/08 |
| ASMANEX HFA | ORGANON LLC | NDA 205641 · Product no. 003 | AEROSOL, METERED | INHALATION | HUMAN PRESCRIPTION DRUG | 2019/08/12 |
| NASONEX 24HR ALLERGY | PERRIGO PHARMA INTERNATIONAL DAC | NDA 215712 · Product no. 001 | SPRAY, METERED | NASAL | HUMAN OTC DRUG | 2022/03/17 |
| ELOCON | ORGANON LLC A SUB OF ORGANON AND CO | NDA 019543 · Product no. 001 | OINTMENT | TOPICAL | DISCONTINUED | 1987/04/30 |
| ELOCON | ORGANON LLC A SUB OF ORGANON AND CO | NDA 019625 · Product no. 001 | CREAM | TOPICAL | DISCONTINUED | 1987/05/06 |
| ELOCON | ORGANON LLC A SUB OF ORGANON AND CO | NDA 019796 · Product no. 001 | LOTION | TOPICAL | DISCONTINUED | 1989/03/30 |
| ELOCON | ORGANON LLC A SUB OF ORGANON AND CO | NDA 019625 · Product no. 002 | CREAM | TOPICAL | DISCONTINUED | 2013/04/19 |
Same-form/route listings come first, followed by other forms/routes. Within each group, source prescription/OTC listings precede discontinued listings; unknown statuses are last. Each status bucket is ordered by earliest approval date, ascending: pre-1982 records first, missing dates last; ties by brand name, application number and product number. The first five distinct brands in this order are selected globally. All retained source facts for those brands are shown in their own groups; a brand spanning both groups counts once.
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.
Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | ||||||
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
Loaded records: 15 distinct approval numbers and 11 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| Shanghai Tong Yong Sai Nuo Pharma Co., Ltd. romanized | 国药准字H20040853 | 0.1% | Category B | XD07ACK037F002010100774 | NHSA |
| Bai Er Pharmaceuticals (Shanghai) Co., Ltd. romanized | 国药准字H19991418 | 0.1%(5g:5mg;10g:10mg;15g:15mg) | Category B | XD07ACK037F002010100784 | NHSA |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20255360 | See source | Category B | XD07ACK037F002010101003 | NHSA |
| Hubei Heng An Fu Lin Pharma Co., Ltd. romanized | 国药准字H20074173 | 10g:10mg | Category B | XD07ACK037F002010101808 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002010101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002010101955 | NHSA |
| Henan Ling Rui Bio Pharma Co., Ltd. romanized | 国药准字H20133348 | See source | Category B | XD07ACK037F002010103049 | NHSA |
| Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized | 国药准字H20050610 | 0.1%(5g:5mg),0.1%(10g:10mg) | Category B | XD07ACK037F002010104735 | NHSA |
| Hua Run San Jiu (Nanchang) Pharma Co., Ltd. romanized | 国药准字H20074090 | 0.1% | Category B | XD07ACK037F002010105411 | NHSA |
| Fu Yuan Pharma Co., Ltd. romanized | 国药准字H20244445 | See source | Category B | XD07ACK037F002010180651 | NHSA |
| Shanghai Tong Yong Sai Nuo Pharma Co., Ltd. romanized | 国药准字H20040853 | 0.1% | Category B | XD07ACK037F002020100774 | NHSA |
| Bai Er Pharmaceuticals (Shanghai) Co., Ltd. romanized | 国药准字H19991418 | 0.1%(5g:5mg;10g:10mg;15g:15mg) | Category B | XD07ACK037F002020100784 | NHSA |
| Chongqing Huapont Pharmaceutical Co., Ltd. | 国药准字H20255359 | See source | Category B | XD07ACK037F002020101003 | NHSA |
| Hubei Heng An Fu Lin Pharma Co., Ltd. romanized | 国药准字H20074173 | 10g:10mg | Category B | XD07ACK037F002020101808 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002020101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002020101955 | NHSA |
| Henan Ling Rui Bio Pharma Co., Ltd. romanized | 国药准字H20113466 | See source | Category B | XD07ACK037F002020103049 | NHSA |
| Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized | 国药准字H20050610 | 0.1%(5g:5mg),0.1%(10g:10mg) | Category B | XD07ACK037F002020104735 | NHSA |
| Dian Hong Pharma Group Co., Ltd. romanized | 国药准字H20083623 | 5g:5mg | Category B | XD07ACK037F002020105583 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002020201827 | NHSA |
| Shanghai Tong Yong Sai Nuo Pharma Co., Ltd. romanized | 国药准字H20040853 | 0.1% | Category B | XD07ACK037F002030100774 | NHSA |
| Bai Er Pharmaceuticals (Shanghai) Co., Ltd. romanized | 国药准字H19991418 | 0.1%(5g:5mg;10g:10mg;15g:15mg) | Category B | XD07ACK037F002030100784 | NHSA |
| Hubei Heng An Fu Lin Pharma Co., Ltd. romanized | 国药准字H20074173 | 10g:10mg | Category B | XD07ACK037F002030101808 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002030101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002030101955 | NHSA |
| Henan Ling Rui Bio Pharma Co., Ltd. romanized | 国药准字H20113466 | See source | Category B | XD07ACK037F002030103049 | NHSA |
| Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized | 国药准字H20050610 | 0.1%(5g:5mg),0.1%(10g:10mg) | Category B | XD07ACK037F002030104735 | NHSA |
| Hua Run San Jiu (Nanchang) Pharma Co., Ltd. romanized | 国药准字H20074090 | 0.1% | Category B | XD07ACK037F002030105411 | NHSA |
| Fu Yuan Pharma Co., Ltd. romanized | 国药准字H20244445 | See source | Category B | XD07ACK037F002030180651 | NHSA |
| Shanghai Tong Yong Sai Nuo Pharma Co., Ltd. romanized | 国药准字H20040853 | 0.1% | Category B | XD07ACK037F002040100774 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002040101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002040101955 | NHSA |
| Henan Ling Rui Bio Pharma Co., Ltd. romanized | 国药准字H20113466 | See source | Category B | XD07ACK037F002040103049 | NHSA |
| Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized | 国药准字H20050610 | 0.1%(5g:5mg),0.1%(10g:10mg) | Category B | XD07ACK037F002040104735 | NHSA |
| Shanghai Tong Yong Sai Nuo Pharma Co., Ltd. romanized | 国药准字H20040853 | 0.1% | Category B | XD07ACK037F002050100774 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002050101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002050101955 | NHSA |
| Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized | 国药准字H20050610 | 0.1%(5g:5mg),0.1%(10g:10mg) | Category B | XD07ACK037F002050104735 | NHSA |
| Fu Yuan Pharma Co., Ltd. romanized | 国药准字H20269111 | 0.1%(5g:5mg) | Category B | XD07ACK037F002050180651 | NHSA |
| Shanghai Tong Yong Sai Nuo Pharma Co., Ltd. romanized | 国药准字H20040853 | 0.1% | Category B | XD07ACK037F002060100774 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002060101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002060101955 | NHSA |
| Fu Yuan Pharma Co., Ltd. romanized | 国药准字H20269159 | 0.1%(10g:10mg) | Category B | XD07ACK037F002060180651 | NHSA |
| Fu Yuan Pharma Co., Ltd. romanized | 国药准字H20269159 | 0.1%(10g:10mg) | Category B | XD07ACK037F002060280651 | NHSA |
| Fu Yuan Pharma Co., Ltd. romanized | 国药准字H20269159 | 0.1%(10g:10mg) | Category B | XD07ACK037F002060380651 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002070101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002070101955 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002080101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002080101955 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002090101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002090101955 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002100101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002100101955 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002110101827 | NHSA |
| Wuhan Nuo An Pharma Co., Ltd. romanized | 国药准字H20173401 | 0.1%(5g:5mg) | Category B | XD07ACK037F002110101955 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002120101827 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002130101827 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002140101827 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002150101827 | NHSA |
| Hubei Ke Tian Pharma Co., Ltd. romanized | 国药准字H20183221 | 0.1%(10g:10mg) | Category B | XD07ACK037F002160101827 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Loaded records: 16 filings and 10 distinct first applicants.
Generic 14 · Supplement 2
Loaded records: 7 filings and 5 distinct first applicants.
Non-component matches: 15 companies with A status and 10 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 糠酸莫米松一水合物 · No verified English name | Tianjin Xin Yi Jin Jin Pharma Co., Ltd. romanized | Y20260000071 | I | Salt-normalized ingredient | 2026/04/09 | CDE |
| 糠酸莫米松 · No verified English name | Bo Ze Ge Lin (Shandong) Pharma Co., Ltd. romanized | Y20240000274 | A | Exact ingredient | 2026/03/06 | CDE |
| 糠酸莫米松 · No verified English name | Aarti Pharmalabs Limited | Y20240000463 | I | Exact ingredient | 2024/10/16 | CDE |
| 糠酸莫米松 · No verified English name | Aarti Pharmalabs Limited | Y20240000462 | I | Exact ingredient | 2024/09/25 | CDE |
| 糠酸莫米松 · No verified English name | Henan Li Hua Pharmaceutical Co., Ltd. romanized | Y20240000595 | A | Exact ingredient | 2026/02/02 | CDE |
| 糠酸莫米松 · No verified English name | Shandong Si Rui Pharma Co., Ltd. romanized | Y20240000435 | A | Exact ingredient | 2025/11/10 | CDE |
| 糠酸莫米松 · No verified English name | Bo Ze Ge Lin (Shandong) Pharma Co., Ltd. romanized | Y20240000273 | A | Exact ingredient | 2026/05/20 | CDE |
| 糠酸莫米松 · No verified English name | Sterling.S.p.A | Y20230001259 | A | Exact ingredient | 2026/10/21 | CDE |
| 糠酸莫米松 · No verified English name | Chongqing Sheng Kai Pharmaceutical Co., Ltd. romanized | Y20230001358 | A | Exact ingredient | 2025/04/22 | CDE |
| 糠酸莫米松 · No verified English name | Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized | Y20230001020 | A | Exact ingredient | 2025/01/15 | CDE |
| 糠酸莫米松 · No verified English name | Ao Rui Te Pharma Co., Ltd. romanized | Y20220001115 | A | Exact ingredient | 2024/06/28 | CDE |
| 糠酸莫米松 · No verified English name | Shandong Rui Shun Pharma Co., Ltd. romanized | Y20220000719 | A | Exact ingredient | 2026/06/19 | CDE |
| 糠酸莫米松 · No verified English name | AVIK PHARMACEUTICAL LTD. | Y20210000968 | A | Exact ingredient | 2023/11/02 | CDE |
| 糠酸莫米松一水合物 · No verified English name | Shandong Rui Shun Pharma Co., Ltd. romanized | Y20210000879 | A | Salt-normalized ingredient | 2026/06/12 | CDE |
| 糠酸莫米松 · No verified English name | STERLING S.P.A. | Y20200000775 | I | Exact ingredient | 2020/12/16 | CDE |
| 糠酸莫米松 · No verified English name | HOVIONE FARMACIENCIA S.A. | Y20200000416 | I | Exact ingredient | 2020/07/02 | CDE |
| 糠酸莫米松 · No verified English name | Xin Xiang Hai Bin Pharma Co., Ltd. romanized | Y20190021417 | I | Exact ingredient | 2020/01/10 | CDE |
| 糠酸莫米松一水合物 · No verified English name | Xin Xiang Hai Bin Pharma Co., Ltd. romanized | Y20190021416 | I | Salt-normalized ingredient | 2020/01/03 | CDE |
| 糠酸莫米松一水合物 · No verified English name | CIPLA LTD. | Y20190001032 | A | Salt-normalized ingredient | 2026/02/07 | CDE |
| 糠酸莫米松 · No verified English name | Jin Yao Pharma Co., Ltd. romanized | Y20190009768 | A | Exact ingredient | 2026/04/04 | CDE |
| 糠酸莫米松 · No verified English name | Shanghai Xin Hua Lian Pharmaceutical Co., Ltd. romanized | Y20190008525 | A | Exact ingredient | 2024/11/28 | CDE |
| 糠酸莫米松 · No verified English name | Zhejiang Xian Ju Pharmaceutical Co., Ltd. romanized | Y20190007547 | A | Exact ingredient | 2026/03/25 | CDE |
| 糠酸莫米松 · No verified English name | Wavelength Enterprises Ltd. | Y20180001760 | A | Exact ingredient | 2022/09/27 | CDE |
| 糠酸莫米松 · No verified English name | Aarti Industries Limited | Y20190000280 | I | Exact ingredient | 2019/04/22 | CDE |
| 糠酸莫米松 · No verified English name | Tianjin Tian Yao Pharma Co., Ltd. romanized | Y20180000685 | I | Exact ingredient | 2018/10/10 | CDE |
| 糠酸莫米松 · No verified English name | Tianjin Tian Yao Pharma Co., Ltd. romanized | Y20180001002 | I | Exact ingredient | 2018/09/06 | CDE |
| 糠酸莫米松 · No verified English name | MSD International GmbH(Singapore Branch) | Y20170001657 | A | Exact ingredient | 2025/10/14 | CDE |
| 糠酸莫米松 · No verified English name | Hubei Heng An Fu Lin Pharma Co., Ltd. romanized | Y20170001175 | A | Exact ingredient | 2023/12/08 | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/13 06:39. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.
CYHS2501034
Fact date: 2026/11/11 · Site observation date: 2026/11/11
Accepted: 2025/03/13
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗CYHS2501033
Fact date: 2026/11/11 · Site observation date: 2026/11/11
Accepted: 2025/03/13
not on the CDE under-review list in this snapshot; the review / approval outcome is to be checked
View source ↗CYHB2602038
Fact date: 2026/11/10 · Site observation date: 2026/11/11
View source ↗CYHB2602037
Fact date: 2026/11/10 · Site observation date: 2026/11/11
View source ↗CYHS2602599
Fact date: 2026/10/22 · Site observation date: 2026/10/23
View source ↗Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 7/30; discovered pending details: 13. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
US$200
Billed every month
Sign in to subscribeUS$540
Billed every three months
US$180 per month
Sign in to subscribeUS$1,920
Billed every year
US$160 per month
Sign in to subscribeSeparate one-time purchase
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy